Vir Biotechnology, Inc. (VIR)
Automate Your Wheel Strategy on VIR
With Tiblio's Option Bot, you can configure your own wheel strategy including VIR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VIR
- Rev/Share 0.1204
- Book/Share 6.8436
- PB 0.8446
- Debt/Equity 0.0986
- CurrentRatio 7.0065
- ROIC -0.5459
- MktCap 802936942.0
- FreeCF/Share -3.3687
- PFCF -1.7216
- PE -1.4543
- Debt/Assets 0.0783
- DivYield 0
- ROE -0.5022
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | VIR | Evercore ISI | -- | Outperform | -- | $12 | Sept. 3, 2025 |
| Upgrade | VIR | BofA Securities | Neutral | Buy | -- | $14 | Aug. 27, 2025 |
News
Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains?
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Vir Biotechnology (VIR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
Vir Biotechnology, Inc. (VIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 16, 2025 by: Seeking Alpha
Sentiment: Neutral
Vir Biotechnology, Inc. (NASDAQ:VIR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:05 PM EDT Company Participants Marianne De Backer - CEO & Director Mark Eisner - Executive VP & Chief Medical Officer Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.
Read More
Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Negative
Vir Biotechnology (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Vir Biotechnology: Hep B And Cancer Projects March On
Published: July 23, 2025 by: Seeking Alpha
Sentiment: Neutral
Vir Biotechnology: Hep B And Cancer Projects March On
Read More
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Vir Biotechnology (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
Published: May 09, 2025 by: Business Wire
Sentiment: Neutral
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced 24-week post-end of treatment data from Part B of the ongoing MARCH Phase 2 clinical study evaluating tobevibart and elebsiran without or with pegylated interferon alpha (PEG-IFNα) in participants with chronic hepatitis B (CHB). The study-defined primary endpoint, proportion of participants with undetectable hepatitis B surface antigen (HBsAg) at 24 weeks post-end of treatment, was achieved by 17% (3/18) and 2.
Read More
Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Positive
Vir Biotechnology, Inc.'s phase 3 ECLIPSE program for HDV, leveraging tobevibart and elebsiran, shows promise based on positive phase 2 SOLSTICE study results. The global hepatitis D market size is projected to surpass $1.05 billion by 2034. VIR-5518 and VIR-5500 are dual-masked HER2 and PSMA T-cell engagers being developed to target solid tumors; The current status of these candidates is that dose-escalation for both are ongoing.
Read More
Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Mark Eisner - Executive Vice President & Chief Medical Officer Jason O'Byrne - Executive Vice President & Chief Financial Officer Mika Derynck - Executive Vice President of Therapeutic Head Oncology Conference Call Participants Gena Wang - Barclays Paul Choi - Goldman Sachs Nick Gasic - Leerink Partners Phil Nadeau - TD Cowen Patrick Trucchio - H.C. Wainwright & Co. Joseph Stringer - Needham & Company Operator Hello.
Read More
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.48 per share a year ago.
Read More
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025
Published: April 24, 2025 by: Business Wire
Sentiment: Neutral
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from a 24-week subgroup analysis of its ongoing Phase 2 SOLSTICE trial in chronic hepatitis delta at the upcoming European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam (The Netherlands), May 7-10. The Company will also present 24 Week post-treatment follow-up data from the MARCH Phase 2 clinical study evaluating combinations of tobevibart and elebsiran,.
Read More
Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Mark Eisner - Executive Vice President & Chief Medical Officer Jason O'Byrne - Executive Vice President & Chief Financial Officer Mika Derynck - Executive Vice President of Therapeutic Head Oncology Conference Call Participants Hang Hu - Barclays Paul Choi - Goldman Sachs Phil Nadeau - TD Cowen Alec Stranahan - Bank of America Joseph Stringer - Needham Patrick Trucchio - H.C. Wainwright & Co. Operator Hello.
Read More
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.86 per share a year ago.
Read More
About Vir Biotechnology, Inc. (VIR)
- IPO Date 2019-10-11
- Website https://www.vir.bio
- Industry Biotechnology
- CEO Marianne De Backer
- Employees 408